ClinicalTrials.gg
Enrolling by invitationNCT07158307PCB-De NovoUpdated Sep 5, 2025

Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion

An observational study in Coronary Artery Disease(CAD), sponsored by Genoss Co., Ltd.. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Genoss Co., Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Coronary Artery Disease by Genoss Co., Ltd. — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Genoss Co., Ltd..

Started
2024
the only one that year
Observational
6 of 10
5 open now
Registered
9th of 10
by date

Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., this one is the only one that started in 2024, is one of 6 observational ones, and was the 9th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

6 of the 10 studies in Coronary Artery Disease by Genoss Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Genoss Co., Ltd., or all of them as a file.
02

Study summary

The GENOSS PCB-De Novo study aims to evaluate the long-term efficacy and safety of a paclitaxel-coated balloon catheter containing shellac and vitamin E excipients (Genoss® DCB) in patients with De novo small coronary artery disease.

Read the detailed description

This prospective, open-label, multicenter, observational study will enroll patients with de novo small coronary artery disease undergoing PCI with the GENOSS® DCB at 47 hospitals.

Because this is an observational study, the number of participants will not be calculated separately, but a total of 3,000 participants are planned to be recruited during the study enrollment period.

All patients will be followed up at 1, 2, and 3 years postprocedure to evaluate the safety and efficacy of the paclitaxel-coated PTCA balloon catheter.

03

Conditions studied

  • Coronary Artery Disease(CAD)
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects who underwent PCI with GENOSS DCB for small coronary artery disease with de novo lesions

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults over the age of 19
  • Patients with new lesions with coronary small vascular disease (vascular diameter \<3.0 mm) underwent a GENOSS® DCB procedure through percutaneous coronary intervention
  • Subjects who agreed to the clinical research plan and the clinical follow-up plan, voluntarily decided to participate in this clinical study, and agreed in writing to the consent of the study subjects

Exclusion criteria

Exclusion Criteria:

  • Subjects who plan to become pregnant during the period of this study as women of the gestational age
  • Subjects whose remaining is expected to be less than one year
  • Subjects who visited the hospital due to psychogenic shock at the time of visiting the hospital and are predicted to have a low chance of survival based on medical judgment
  • If it falls under any of the following items after prior dilation of the target lesion;

    • Stent procedures are required due to vascular detachment that limits blood flow
    • If the residual stenosis is >30%
    • If the TIMI flow is \<3
  • Subjects participating in a randomized study of medical devices
  • If the researcher determines that it is not appropriate for this clinical study or may increase the risk associated with participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • GENOSS® DCB (Paclitaxel-coated PTCA Balloon Catheter)

    Patients with de novo small coronary artery disease who underwent PCI with GENOSS DCB

06

What researchers measure

Primary outcomes

  1. Target lesion failure (TLF)

    composite endpoint of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization

    Time frame: at 1 year after the procedure

Secondary outcomes

  1. Target lesion failure (TLF)

    composite endpoint of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization

    Time frame: at 2, 3 years after the procedure

  2. Major cardiac adverse events (MACE)

    composite endpoint of death, myocardial infarction, and revascularization

    Time frame: at 1, 2, 3 years after the procedure

  3. all mortality

    all deaths and cardiac deaths

    Time frame: at 1, 2, 3 years after the procedure

  4. any MI

    all myocardial infarction and target vessel myocardial infarction (TV-MI)

    Time frame: at 1, 2, 3 years after the procedure

  5. all revascularization and ischemia-driven target lesion revascularization (ID-TLR)

    Time frame: at 1, 2, 3 years after the procedure

  6. major bleeding event

    BARC 3, 5

    Time frame: at 1, 2, 3 years after the procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2030, 72 months after the start.

Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 72 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 5, 2025
StartActual
Jun 27, 2024
Primary completionEst.
Jun 27, 2030
CompletionEst.
Jun 30, 2031
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07158307
Lead sponsor
Genoss Co., Ltd.
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Jun 27, 2024
Primary completion
Jun 27, 2030 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Sep 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion